CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced the pricing of an underwritten public offering of (i) 7,394,363 shares of common stock (or common stock equivalents in lieu thereof) and (ii) accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock.

2023年9月29日（GLOBE NEWSWIRE）-Synlogic，Inc.（纳斯达克股票代码：SYBX），一家临床阶段生物技术公司，致力于推进新型，口服，非系统吸收的生物治疗药物，以改变严重疾病的治疗，今天宣布了（i）7394363股普通股（或代替普通股等价物）和（ii）随附普通股权证购买多达7394363股普通股的承保公开发行的定价。

The combined effective offering price to the public of each share of common stock (or pre-funded warrant) and accompanying warrant is $2.84. The accompanying warrants will have an exercise price of $3.408 per share, will be exercisable immediately, and will expire five years from the initial exercise date.

每股普通股（或预先资助的认股权证）及随附认股权证向公众的合并有效发行价格为2.84美元。随附认股权证的行使价为每股3.408美元，可立即行使，并将于首次行使日期起五年到期。

All of the securities are being offered by Synlogic, Inc. The Company expects to receive total gross proceeds of approximately $21.0 million, before deducting underwriting discounts, commissions and offering expenses. The offering is expected to close on or about October 3, 2023, subject to satisfaction of customary closing conditions.

所有证券均由Synlogic，Inc。提供。公司预计在扣除承保折扣，佣金和提供费用之前，将获得约2100万美元的总收益。在满足习惯性关闭条件的前提下，预计该产品将于2023年10月3日或之后关闭。

Chardan is acting as sole book-running manager for the offering. The securities will be offered pursuant to a registration statement on Form S-1, as amended (File No. 333-274421), which was declared effective by the Securities and Exchange Commission (the 'SEC') on September 28, 2023. The offering is being made solely by means of a prospectus.

Chardan是该产品的唯一图书运营经理。证券将根据经修订的表格S-1（文件号333-274421）的注册声明提供，该声明已于2023年9月28日由证券交易委员会（“SEC”）宣布生效。该产品仅通过IPO进行。

A preliminary prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus and, when available, copies of the final prospectus relating to this offering can be obtained at the SEC's website at www.s.

有关并描述该产品条款的初步承销说明书已向证券交易委员会提交，并可在证券交易委员会网站www.SEC.gov上查阅。初步承销说明书的副本以及与此相关的最终承销说明书副本。可在证券交易委员会网站www.s.获取。